Edition:
United Kingdom

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

61.99USD
2:32pm GMT
Change (% chg)

$0.38 (+0.62%)
Prev Close
$61.61
Open
$62.05
Day's High
$62.11
Day's Low
$61.99
Volume
7,353
Avg. Vol
388,025
52-wk High
$135.59
52-wk Low
$54.98

Latest Key Developments (Source: Significant Developments)

Intercept Pharma reports qtrly ‍revenue $41.3 mln vs $5.2 million​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Intercept Pharmaceuticals Inc :Intercept Pharmaceuticals reports third quarter 2017 financial results and provides business update.Intercept - ‍non-GAAP adjusted operating expenses for fiscal year ending Dec 31, 2017 will fall in middle of range of $380 million to $420 million​.Intercept Pharmaceuticals - ‍interim analysis in flagship Phase 3 regenerate trial on track to report in H1 2019.Intercept Pharmaceuticals Inc- to streamline operating expenses, decided to deprioritize interest-767 development program for foreseeable future​.Intercept Pharmaceuticals Inc - qtrly ‍rev $41.3 million versus $5.2 million​.Q3 earnings per share view $-3.38, revenue view $37.0 million -- Thomson Reuters I/B/E/S.Intercept Pharmaceuticals inc qtrly net loss per common and potential common share basic and diluted $2.89‍​.  Full Article

Intercept Pharma posts positive results from Phase 2 AESOP trial
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Intercept Pharmaceuticals Inc :Intercept announces positive results from Phase 2 AESOP trial evaluating OCA for the treatment of patients with primary sclerosing cholangitis at The Liver Meeting 2017.Intercept Pharmaceuticals Inc - ‍OCA met primary endpoint of alkaline phosphatase (ALP) reduction at 24 weeks​.  Full Article

Intercept extends strategic partnership with Target PharmaSolutions for Target-Nash
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Intercept Pharmaceuticals Inc :Intercept (ICPT) extends strategic partnership with Target PharmaSolutions for Target-Nash.Target PharmaSolutions - Intercept has extended its strategic partnership for Target-Nash to a multi-year agreement​.  Full Article

Intercept Pharmaceuticals Q3 sales $4.7 million
Thursday, 3 Nov 2016 

Intercept Pharmaceuticals Inc : Intercept pharmaceuticals inc- eu marketing approval decision for ocaliva anticipated by year end 2016 . Intercept pharmaceuticals inc- eu launch of ocaliva anticipated in early 2017 . Intercept pharmaceuticals reports third quarter 2016 financial results and provides business update .Q3 sales $4.7 million versus i/b/e/s view $4.8 million.  Full Article

EMA recommends conditional approval of Abbvie leukemia drug
Friday, 14 Oct 2016 

European Medicines Agency(EMA): EU Medicines Agency recommendations for October 2016 . EU Medicines Agency recommends approval of Abbvie Inc’S Venetoclax/Venclexta to treat leukaemia . EU Medicines Agency recommends conditional marketing approval of Intercept Pharmaceuticals Inc’S Ocaliva to treat primary biliary cirrhosis Link to source: (http://bit.ly/2dYKT7R) (Bengaluru Newsroom) ((+91 806 749 1136;)).  Full Article

Intercept Pharmaceuticals Q2 net loss per share $3.14
Thursday, 4 Aug 2016 

Intercept Pharmaceuticals Inc : Intercept pharmaceuticals reports second quarter 2016 financial results and provides business update . Net ocaliva 2q sales of $75,000 shipped to patients, $2.7 million recorded as deferred revenue . Q2 earnings per share view $-3.70, revenue view $1.5 million -- Thomson Reuters I/B/E/S . Qtrly net loss per share diluted $3.14 .Qtrly total revenue $5.5 million versus $445,000.  Full Article

Intercept Pharmaceuticals announces pricing of public offering
Thursday, 30 Jun 2016 

Intercept Pharmaceuticals Inc :Intercept Pharmaceuticals announces pricing of public offering of convertible senior notes.  Full Article

Intercept Pharmaceuticals files for convertible senior notes for up to $400 mln
Wednesday, 29 Jun 2016 

Intercept Pharmaceuticals Inc :Files for convertible senior notes for up to $400 million - SEC filing.  Full Article

Intercept Pharmaceuticals announces public offering of convertible senior notes
Wednesday, 29 Jun 2016 

Intercept Pharmaceuticals Inc : Announces public offering of convertible senior notes . Says commenced an underwritten public offering of $400 million aggregate principal amount of convertible senior notes due 2023 .Says intends to use a portion of net proceeds from offering to fund payment of cost of capped call transactions.  Full Article

BRIEF-Intercept Pharma reports qtrly ‍revenue $41.3 mln vs $5.2 million​

* Intercept Pharmaceuticals reports third quarter 2017 financial results and provides business update